Pfizer gene therapy gets hemophilia B approval in Canada, setting stage for CSL rivalry
Pfizer has secured an approval for its gene therapy for hemophilia B in Canada, months ahead of an expected decision in the US.
The approval sets up a rivalry with CSL Behring’s gene therapy Hemgenix, which was cleared for use in the US in November 2022 and in Canada this past October. Hemgenix was the first gene therapy approved for hemophilia B, a rare genetic disease caused by the deficiency of a protein called factor IX, which helps blood clot. Patients are at risk of dangerous bleeds and often need life-long treatment with factor IX.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
